Appendix K: Evidence review flow charts

Similar documents
Dementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018

Appendix L: Research recommendations

NICE Quality Standards and commissioning dementia care

Delirium. Quick reference guide. Issue date: July Diagnosis, prevention and management

Appendix 2017UEMS031

Summary of funded Dementia Research Projects

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

Understanding Dementia

Supplementary Online Content

Alzheimer Disease Agents Drug Class Prior Authorization Protocol

If you have dementia, you may have some or all of the following symptoms.

Executive Summary. The Royal Australasian College of Physicians July 2012 Page 1 of 5

This information explains the advice about supporting people with dementia and their carers that is set out in NICE SCIE clinical guideline 42.

From MCI to Dementia DR YU- MIN LIN GERIATRICIAN AUG 2018

Drugs used to relieve behavioural and psychological symptoms in dementia

Multi-morbidity in Dementia: A 21st Century Challenge. Sube Banerjee. Professor of Dementia Brighton and Sussex Medical School

Rational Medication Use in Dementia

Dr Georgina Train Consultant Psychiatrist EMDASS service and Continuing Care.

Appendix N: Research recommendations

Alzheimer s disease Treatment options

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

SHARED CARE PROTOCOL CHOLINESTERASE INHIBITORS IN ALZHEIMER S DEMENTIA

What are we getting right and what are we getting wrong?

Medications for Alzheimer s disease: are they right for you?

Drug treatments for Alzheimer s disease

Prescribing Framework for Galantamine in the Treatment and Management of Dementia

Dementia Alistair Burns National Clinical Director for Dementia

Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia

Understanding Dementia

Dementia and cognitive decline

Westminster Memory Services Pathways Toolkit (updated October 2016)

PD ExpertBriefing: Cognition and PD: What You ve Always Wanted to Know But Were Too Afraid to Ask. Presented By: Tuesday, March 22, 2011 at 1:00 PM ET

Young onset dementia service Doncaster

What is dementia? alzheimers.org.uk

Drugs for behavioural and psychological symptoms in dementia

What is dementia? Symptoms. alzheimers.org.uk

Parkinson s disease stakeholder workshop notes

Aricept, Exelon and Reminyl the new drugs for Alzheimer s disease

KNOWSLEY JSNA REPORT. D e m e n t i a. J S N A R e p o r t. January 2016

Community Pharmacy Dementia Audit

Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia

South Tees Hospitals NHS Foundation Trust. Excellence in dementia care across general hospital and community settings. Competency framework

Memory Loss, Dementia and Alzheimer's Disease: The Basics

Essential Shared Care Agreement Drugs for Dementia

Dementia. Memory Evaluation Center Neurology

Evidence-based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine

Neurocognitive Disorders Research to Emerging Therapies

Dementia and Fall Geriatric Interprofessional Training. Wael Hamade, MD, FAAFP

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA 111)

Improving the Lives of People with Dementia

Clinical guideline Published: 22 November 2006 nice.org.uk/guidance/cg42

Understanding dementia

Dementia Care Pathway

Joint Commissioning Panel for Mental Health

CLINICAL PRACTICE GUIDELINES AND PRINCIPLES OF CARE FOR PEOPLE WITH DEMENTIA

Dementia Data Quality Toolkit. Frequently asked questions

Drug Update. Treatments for Cognitive Impairment in the Older Adult. William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle

Dementia Support. Your guide to local support in the Royal Borough of Greenwich. Royal Borough of Greenwich May Supported by

Known as both a thief and murderer,

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)

Current Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE

Disclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA

Questionnaire on National Care Pathways for People with Dementia Living at Home

Pharmacological Treatment of Dementia

What is dementia? What is dementia?

Personal Reflections on the Design and Delivery of Services to Those with Cognitive Disorders

Early dementia. Optimal management in general practice. Issues in aging. What is dementia? Background. Objective. Discussion

Medications for treating people with dementia: summary of evidence on cost-effectiveness

Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital

Evaluations. Alzheimer s Disease A Public Health Response. Viewer Call-In. July 19, Guest Speakers. Thanks to our Sponsors:

Dementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician

DEMENTIA AND MEDICATION

Forgetfulness: Knowing When to Ask for Help

Donepezil, Rivastigmine and Galantamine (TLS Amber with shared care) Donepezil (TLS green Wilts)

Prescribing for people with dementia. Carol Paton Chief Pharmacist April 2009

Understanding Parkinson s for health and social care staff. The phases of Parkinson s

Triage in Aged Persons Mental Health. David McMillan Clinical Nurse Consultant Caulfield Hospital Alfred Health

Coding clean-up Exercise Guidance to GPs to improve dementia coding, and raise diagnosis rates. A step by step approach

Essential Shared Care Agreement Drugs for Dementia

Of those with dementia have a formal diagnosis or are in contact with specialist services. Dementia prevalence for those aged 80+

Dementia. Supporting people with dementia and their carers in health and social care. NICE clinical guideline 42. Issue date: November 2006

PROJECTION: Worlds dementia population is expected to triple by 2050

BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA

Diagnosis and assessment

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Dementia: the management of dementia, including the use of antipsychotic medication in older people

EFFECTIVE SHARED CARE AGREEMENT (ESCA)

v1.4 Reformatted (content numbered) 28/06/12 v1.3 Updated with content identified during Stage 1 blueprinting 23/04/12

Session outline. Introduction to depression Assessment of depression Management of depression Follow-up Review

What is dementia? Contents. Factsheet 400LP January 2017

Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE

Dementia: Post Diagnostic Support Project

Dementia Diagnosis Guidelines Primary Care

Beyond memory loss. March 5, Alzheimer s Overview. In partnership with. Mary Ball President & CEO

OLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia.

The Basics of Alzheimer s Disease

MANAGEMENT OF PATIENT WITH DEMENTIA SSA PERSPECTIVE

WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by

Psychotropic Strategies Handout Package

Transcription:

K.1 Dementia diagnosis K.1.1 Dementia diagnosis What are the most effective methods of primary assessment to decide whether a person with suspected dementia should be referred to a dementia service? What are the most effective methods of diagnosing dementia and dementia subtypes in specialist dementia diagnostic services? 1

K.1.1.1 Systematic reviews 2

K.1.1.2 Primary studies 3

K.1.2 Distinguishing dementia from delirium or delirium with dementia What are the most effective methods of differentiating dementia or dementia with delirium from delirium alone? 4

K.1.3 Case finding for people at high risk of dementia What are the most effective methods of case finding for people at high risk of dementia? 5

K.2 Involving people with dementia in decision about care K.2.1 Barriers and facilitators to involvement in decision making for people living with dementia What barriers and facilitators have an impact on involving people living with dementia in decisions about their present and future care? What barriers and facilitators have an impact on how people living with dementia can make use of advance planning? 6

K.3 Care planning, review and co-ordination K.3.1 K.3.1.1 Health and social care co-ordination What are the most effective methods of care planning, focussing upon improving outcomes for people with dementia and their carers? How should health and social care be co-ordinated for people living with dementia? Qualitative evidence 7

K.3.1.2 Quantitative evidence 8

K.3.2 Post diagnosis review for people living with dementia How should people living with dementia be reviewed post diagnosis? 9

K.4 Inpatient care K.4.1 Caring for people living with dementia who are admitted to hospital How should people living with dementia be cared for when admitted to hospital? 10

K.5 Care setting transitions K.5.1 Managing the transition between different settings for people living with dementia What are the most effective ways of managing the transition between different settings (home, care home, hospital, and respite) for people living with dementia? 11

K.6 Modifying risk factors for dementia progression K.6.1 Risk factors for dementia progression What effect does modifying risk factors have on slowing the progression of dementia? 12

K.7 Cholinesterase inhibitors and memantine for dementia K.7.1 Cholinesterase inhibitors and memantine for people living with Alzheimer s disease Who should start and review the following pharmacological interventions: (donepezil, galantamine, rivastigmine, memantine) for people with Alzheimer's disease and how should a review be carried out? 13

K.7.2 Cholinesterase inhibitors and memantine in Alzheimer s disease How effective is the co-prescription of cholinesterase inhibitors and memantine for the treatment of Alzheimer s disease? 14

When should treatment with donepezil, galantamine, rivastigmine, memantine be withdrawn for people with Alzheimer s disease? 15

K.7.3 Pharmacological management of dementia with Lewy bodies Review question What is the comparative effectiveness of donepezil, galantamine, memantine and rivastigmine for cognitive enhancement in dementia associated with Parkinson s disease? 16

K.7.4 Cholinesterase inhibitors and memantine for types of dementia other than typical Alzheimer s disease How effective are cholinesterase inhibitors and memantine for types of dementia other than typical Alzheimer s disease? 17

K.8 Drugs that may worsen cognitive decline K.8.1 Drugs that may cause cognitive decline What drugs that may worsen cognitive decline are commonly prescribed in people diagnosed with dementia? No search was carried out. See appendix N for the data provided by an expert witness for this review question. 18

What are the most effective tools to identify whether drugs may be the cause of cognitive decline in someone suspected of having dementia? 19

K.9 Non-pharmacological interventions for people living with dementia K.9.1 Non-pharmacological interventions for people living with dementia What are the most effective non-pharmacological interventions for supporting cognitive functioning in people living with dementia? What are the most effective non-pharmacological interventions for supporting functional ability in people living with dementia? What are the most effective non-pharmacological interventions to support wellbeing in people living with dementia? See Appendix O for details K.9.2 Supporting independence in people living with dementia What are the most effective methods of supporting people living with dementia to reduce harm and stay independent? 20

K.9.3 Pre, peri and post-diagnostic counselling and support for people living with dementia and their families How effective are pre, peri & post-diagnostic counselling and support on outcomes for people living with dementia and their families? 21

K.10 Managing non-cognitive symptoms K.10.1 Interventions for treating illness emergent non-cognitive symptoms in people living with dementia What are the most effective pharmacological interventions for managing illness emergent non-cognitive symptoms, such as psychosis, depression, behavioural changes in people living with dementia? What are the most effective non-pharmacological interventions for managing illness emergent non-cognitive symptoms, such as psychosis, depression, behavioural changes in people living with dementia? 22

K.11 Supporting informal carers K.11.1 Supporting informal carers of people living with dementia How effective are carers assessments in identifying the needs of informal carers of people living with dementia? What interventions/services are most effective for supporting the wellbeing of informal carers of people living with dementia? 23

K.12 Staff training K.12.1 K.12.1.1 Staff training What effect does training for staff working with people living with dementia have upon the experiences of people living with dementia in their care? Qualitative search 24

K.13 Needs of younger people living with dementia K.13.1 The specific needs of younger people living with dementia What are the specific needs of younger people living with dementia? 25

K.14 Assessing and managing comorbidities K.14.1 Assessing and treating intercurrent illness in people living with dementia Are there effective methods for assessing intercurrent illness in people living with dementia that are different from those already in use for people who do not have dementia? Are there effective methods for treating intercurrent illness in people living with dementia that are different from those already in use for people who do not have dementia? 26

K.14.2 Management strategies for people living with dementia and co-existing physical long term conditions What are the optimal management strategies (including treatments) for people living with dementia with co-existing physical long term conditions? 27

K.14.3 Managing mental health conditions alongside dementia What are the optimal management strategies (including treatments) for people with dementia and an enduring mental health condition? 28

K.15 Palliative care: care towards and at the end of life K.15.1 K.15.1.1 Palliative care What models of palliative care are effective for people with dementia? Qualitative search 29

K.16 Rerun searches 30